Acute kidney injury

Last updated: September 11, 2023

Summarytoggle arrow icon

Acute kidney injury (AKI) is a sudden loss of renal function with a subsequent rise in creatinine and blood urea nitrogen (BUN). It is most frequently caused by decreased renal perfusion (prerenal) but may also be due to direct damage to the kidneys (intrarenal or intrinsic) or inadequate urine drainage (postrenal). In AKI, the acid-base, fluid, and electrolyte balances are disturbed and the urinary excretion of substances such as drugs is impaired. AKI may be asymptomatic or manifest with oliguria or anuria and, when kidney dysfunction is severe, it may manifest with symptoms and signs of uremia; in some cases, polyuria may occur as a result of impaired tubular reabsorption. A diagnosis of AKI can be made based on an increase in serum creatinine concentration and/or decrease in urine output. Initial evaluation includes blood and urine studies, which may help identify the mechanism of kidney injury and any metabolic complications of AKI. Additional specific investigations are guided by the suspected cause. Rapid evaluation, diagnosis, and treatment are necessary to prevent irreversible loss of renal function. Management is based on the mechanism of kidney injury and the underlying causes. Treatment is primarily supportive and aims to ensure adequate kidney perfusion and prevent complications and further kidney damage.

Etiologytoggle arrow icon

Prerenal acute kidney injury [1][2][3]

Prerenal causes include any condition that leads to decreased renal perfusion (∼ 60% of cases of AKI). [1][2][3]

Prolonged prerenal injury leads to intrinsic injury, as decreased renal perfusion causes tubular necrosis.

Intrinsic acute kidney injury

Intrinsic causes include any condition that leads to severe direct kidney damage (∼ 35% of cases of AKI). [1][2][3]

Postrenal acute kidney injury

Postrenal causes include any condition that results in bilateral obstruction of urinary flow from the renal pelvis to the urethra (∼ 5% of cases of AKI). [1][2][3]

As long as the contralateral kidney remains intact, patients with unilateral ureteral obstruction typically maintain normal serum creatinine levels.

Overview of nephrotoxic medications

Pathophysiologytoggle arrow icon



  • Damage to a vascular or tubular component of the nephron necrosis or apoptosis of tubular cells → decreased reabsorption capacity of electrolytes (e.g., Na+), water, and/or urea; (depending on the location of injury along the tubular system) → increased Na+ and H2O in the urine → decreased urine osmolality


Four phases of AKI

Overview of the four phases of AKI
Phase Characteristic features (some patients may not undergo all phases) Duration

Initiating event (kidney injury)

  • Symptoms of the underlying illness causing AKI may be present.
  • Hours to days

Oliguric or anuric phase (maintenance phase)

  • 1–3 weeks

Polyuric/diuretic phase

  • ∼ 2 weeks

Recovery phase

  • Months to years


Clinical featurestoggle arrow icon

Subtypes and variantstoggle arrow icon

Acute tubular necrosis

Renal cortical necrosis

Contrast-induced nephropathy


Diagnosticstoggle arrow icon

A diagnosis of AKI can be made based on an acute increase in serum creatinine and/or decrease in urine output in accordance with the definition of AKI.

Approach [7][8][9]

  • Compare current and previous creatinine levels to determine if the process is acute.
  • Check diagnostic criteria and perform staging of AKI.
  • Determine the most likely mechanism of AKI (i.e., prerenal, intrinsic, or postrenal) based on:
    • A comprehensive chart review, history, and physical examination
    • Supportive diagnostic findings and response to initial interventions
  • Consider further testing for specific underlying causes of AKI.

In the absence of previously documented creatinine levels, stable creatinine levels with findings such as chronic anemia and small hyperechoic kidneys on ultrasound suggest CKD rather than AKI.

Clinical presentation, laboratory tests, imaging, response to initial therapy, and, in some cases, histopathology are required to determine the underlying cause of AKI.

Diagnostic criteria of acute kidney injury

  • Acute kidney injury is defined as the presence of any of the following criteria: ; [7]
    • Increase in serum creatinine by ≥ 0.3 mg/dL (26.5 μmol/L) within 48 hours.
    • Increase in serum creatinine to ≥ 1.5 times baseline level within 7 days.
    • Decrease in urine output to < 0.5 mL/kg/hour for ≥ 6 hours.

Staging of acute kidney injury

  • The KDIGO stages are widely used and correlate with the risk of death, need for renal replacement therapy, and long-term outcomes (e.g., CKD).
  • Other classifications include: [7]
    • RIFLE criteria: A classification system for acute kidney injury
      • The acronym stands for Risk, Injury, Failure, Loss, and End-stage kidney disease.
      • For the first three categories, patients are classified according to the level of kidney injury (i.e., degree of increase in serum creatinine and/or decrease in GFR and urine output) and for the last two categories, according to the duration of complete loss of kidney function.
    • Acute Kidney Injury Network (AKIN) criteria
Kidney Disease Improving Global outcomes (KDIGO) criteria for staging of AKI [7]
Stage Serum creatinine Urine output
AKI stage 1
  • Increase of 0.3 mg/dL (26.5 μmol/L)
  • OR 1.5–1.9 times baseline
  • < 0.5 mL/kg/hour for 6–12 hours
AKI stage 2
  • 2.0–2.9 times baseline
  • < 0.5 mL/kg/hour for ≥12 hours
AKI stage 3
  • ≥ 3 times baseline
  • OR increase to ≥ 4 mg/dL (354 μmol/L)
  • OR renal replacement therapy initiated
  • OR in patients < 18 years of age: decrease in eGFR to < 35 mL/min/1.73 m2
  • < 0.3 mL/kg/hour for ≥ 24 hours
  • OR anuria for ≥ 12 hours
If serum creatinine and urine output correlate with different stages, consider staging based on the criterion that corresponds to the highest stage. [9]

Initial evaluation

Laboratory studies

Overview of diagnostic findings

Determination of the likely mechanism of acute kidney injury
Prerenal Intrinsic Postrenal
BUN:creatinine ratio
  • > 20:1
  • < 15:1
  • Varies


  • < 1%
  • > 2–3%
  • < 35%
  • > 50%
Urine sodium concentration
  • < 20 mEq/L
  • > 40 mEq/L
Urine osmolality
  • > 500 mOsm/kg
  • < 350 mOsm/kg
  • < 350 mOsm/kg
Urine sediment

Despite the common use of BUN:creatinine ratio and urinary fractional excretions (i.e., FENa, FEUrea) in clinical practice, observational data suggest that they do not reliably distinguish prerenal AKI from intrinsic AKI. [10][11]

The most likely mechanism of AKI is primarily determined based on clinical presentation and response to therapy. Evaluating patients' response to initial interventions is key to confirming the mechanism of AKI and guiding further workup and management steps.

Prerenal AKI [8][9]

Patients with prerenal AKI receiving diuretic therapy may have a falsely elevated FENa. Therefore, FEUrea may be more informative in this setting. [15]

Intrinsic AKI

A falsely low FENa may be seen in some patients with intrinsic AKI, e.g., due to glomerulonephritis, acute interstitial nephritis, rhabdomyolysis, or contrast-induced nephropathy. [15]

Postrenal AKI

Additional evaluation

Imaging [17]

Imaging of the kidneys and urinary tract is not necessary to establish a diagnosis of AKI but may be needed to determine the etiology.

Obtain an urgent ultrasound to rule out hydronephrosis in patients with risk factors for urinary tract obstruction.

While ultrasound is the initial test of choice to assess for urinary tract obstruction, CT has greater sensitivity for detecting obstructions and stones. [19]

Renal biopsy [8][20]

  • Not routinely indicated
  • Consider if:
    • The cause of AKI cannot be identified after a thorough initial evaluation
    • Diagnostic confirmation of the cause (e.g., glomerulonephritis, myeloma nephropathy) is needed prior to initiating disease-specific therapy

Additional specific testing

Usually reserved for cases in which intrinsic AKI is initially suspected or interventions aimed at reversing presumed prerenal AKI or postrenal AKI fail to improve renal function. Studies should be guided by clinical suspicion.

Noninvasive testing for specific underlying causes of AKI [1][20]
Examples Characteristic clinical features Diagnostic findings
Nephrotoxin-induced AKI
Rapidly progressive glomerulonephritis
  • ANA
  • ↑ dsDNA
  • ↓ Complement
  • ↑ Serum IgA
  • Normal complement
  • Exposure to typical culprit medications
  • Fever, drug rash, flank pain

Managementtoggle arrow icon

Approach [7][8][9]

AKI management is primarily supportive. Currently, there are no specific pharmacotherapies for AKI. [9]

Avoid coadministering RAAS inhibitors and NSAIDs in patients with reduced renal perfusion (e.g., in congestive heart failure, renal artery stenosis) because doing so can significantly decrease their GFR.

Early nephrology consult

Treatment of underlying causes [7][8][9]

Treatment for the underlying cause of AKI
AKI subtype Cause Management
  • Discontinuation of offending medications (e.g., ACE-Is, ARBs, NSAIDs)
  • Ensure adequate hydration.
  • Supportive care of AKI (mainstay of treatment) including prevention of further nephrotoxin exposure [25]
  • Management of any complications
  • Vascular causes
  • Ureteral or renal pelvic obstruction

The longer the underlying cause has been present, the greater the chance that AKI will progress to renal failure and/or CKD. Treat potential causes of AKI early.

Renal replacement therapy [7][9]

See also “Indications for acute dialysis.”

Supportive care and follow-uptoggle arrow icon

The goal of supportive care is to avoid further renal insult and potentially aggravating factors, support adequate kidney perfusion, and ensure early identification and treatment of complications.

Medications and nephrotoxic substances [9]

Calculating eGFR using conventional equations does not accurately predict the true GFR in patients with AKI. Reestimate GFR daily based on the patient's urine output and the trajectory of serum creatinine.

Noncontrast imaging studies are preferred if possible. When the use of iodinated contrast is required for a critical diagnostic study or procedure (e.g., for the treatment of STEMI), the lowest clinical diagnostic dose should be used.

Volume status and blood pressure [8][9]

Hemodynamic support in patients with AKI according to presumed intravascular volume status

Hypovolemia (and/or hypotension)
Euvolemia or indeterminate volume status

Patients with AKI are at high risk of developing fluid overload, which can compromise renal function and may increase mortality. Avoid aggressive fluid resuscitation in patients who are not volume responsive.

Consider loop diuretics ONLY in patients with signs of fluid overload. Diuretics should not be used routinely to improve urine output in patients with AKI because of their lack of benefit and potential for harm. [7]

Choice of parenteral fluid [8][9][30]

The use of balanced IV fluid solutions has been associated with lower mortality and better renal outcomes compared with the use of normal saline in patients with AKI.

Electrolyte and acid-base disorders

Obtain frequent (at least daily) laboratory studies to monitor for the presence of metabolic complications and response to treatment (e.g., improvement in creatinine levels).

Consider urgent renal replacement therapy for patients with refractory electrolyte or acid-base disturbances.

Additional considerations

The risk of GI bleeding may be increased in AKI due to uremic platelet dysfunction. [37]

Consider a nutrition consult for all patients with AKI. [35]

Follow-up care [38][39]

  • Educate patients on medication management and the prevention of AKI.
  • Monitor serum creatinine, eGFR, blood pressure, and weight following discharge. [38][40]
  • Ensure that patients who require ongoing renal replacement therapy have access to outpatient dialysis services.
  • Consider referral for outpatient nephrology follow-up in patients with significant residual renal dysfunction (i.e., eGFR < 60 mL/min).

Patients who recover from AKI are at high risk of readmission, mortality, cardiovascular events, progressive renal function deterioration, and developing de novo CKD. [38][39]

Adequate discharge planning and follow-up may help improve patient outcomes. [38][39]

Acute management checklisttoggle arrow icon

Special patient groupstoggle arrow icon

Neonatal acute kidney injury [41][42][43]

Preventiontoggle arrow icon

Identify patients who are at risk of AKI and implement appropriate preventive strategies. [1][7][22]

Prevention of acute kidney injury
Risk factors Preventive strategies
Acute illness
Nephrotoxic medication exposure
Iodinated radiocontrast agent exposure
Liver failure
Endogenous nephrotoxins

Related One-Minute Telegramtoggle arrow icon

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

Referencestoggle arrow icon

  1. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Updated: January 1, 2012. Accessed: September 19, 2020.
  2. Mercado MG, Smith DK, Guard EL. Acute Kidney Injury: Diagnosis and Management.. Am Fam Physician. 2019; 100 (11): p.687-694.
  3. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. American Journal of Kidney Diseases. 2018; 72 (1): p.136-148.doi: 10.1053/j.ajkd.2017.11.021 . | Open in Read by QxMD
  4. Acute kidney injury: prevention, detection, and management. Updated: December 18, 2019. Accessed: September 23, 2020.
  5. Esson ML. Diagnosis and Treatment of Acute Tubular Necrosis. Ann Intern Med. 2002; 137 (9): p.744.doi: 10.7326/0003-4819-137-9-200211050-00010 . | Open in Read by QxMD
  6. Ramoutar V, Landa C, James LR. Acute tubular necrosis (ATN) presenting with an unusually prolonged period of marked polyuria heralded by an abrupt oliguric phase. Case Reports. 2014; 2014 (aug22 1): p.bcr2013201030-bcr2013201030.doi: 10.1136/bcr-2013-201030 . | Open in Read by QxMD
  7. Ali A, Bhan C, Malik MB, Ahmad MQ, Sami SA. The Prevention and Management of Contrast-induced Acute Kidney Injury: A Mini-review of the Literature. Cureus. 2018.doi: 10.7759/cureus.3284 . | Open in Read by QxMD
  8. Ghossein C, Varga J, Fenves AZ. Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis. Curr Rheumatol Rep. 2015; 18 (1).doi: 10.1007/s11926-015-0551-y . | Open in Read by QxMD
  9. Pelletier K, Lafrance J-P, Roy L, et al. Estimating glomerular filtration rate in patients with acute kidney injury: a prospective multicenter study of diagnostic accuracy. Nephrology Dialysis Transplantation. 2019; 35 (11): p.1886-1893.doi: 10.1093/ndt/gfz178 . | Open in Read by QxMD
  10. Bairy M. Using Kinetic eGFR for Drug Dosing in AKI: Concordance between Kinetic eGFR, Cockroft-Gault Estimated Creatinine Clearance, and MDRD eGFR for Drug Dosing Categories in a Pilot Study Cohort. Nephron. 2020; 144 (6): p.299-303.doi: 10.1159/000507260 . | Open in Read by QxMD
  11. Chen S. Retooling the Creatinine Clearance Equation to Estimate Kinetic GFR when the Plasma Creatinine Is Changing Acutely. J Am Soc Nephrol. 2013; 24 (6): p.877-888.doi: 10.1681/asn.2012070653 . | Open in Read by QxMD
  12. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nature Reviews Nephrology. 2013; 10 (1): p.37-47.doi: 10.1038/nrneph.2013.232 . | Open in Read by QxMD
  13. Sola E, Guevara M, Gines P. Current treatment strategies for hepatorenal syndrome. Clin Liver Dis (Hoboken). 2013; 2 (3): p.136-139.doi: 10.1002/cld.209 . | Open in Read by QxMD
  14. Salerno F, Navickis RJ, Wilkes MM. Albumin Infusion Improves Outcomes of Patients With Spontaneous Bacterial Peritonitis: A Meta-analysis of Randomized Trials. Clinical Gastroenterology and Hepatology. 2013; 11 (2): p.123-130.e1.doi: 10.1016/j.cgh.2012.11.007 . | Open in Read by QxMD
  15. Duffy M, Jain S, Harrell N, Kothari N, Reddi AS. Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies.. Cells. 2015; 4 (4): p.622-30.doi: 10.3390/cells4040622 . | Open in Read by QxMD
  16. Leaf DE, Christov M. Dysregulated Mineral Metabolism in AKI. Semin Nephrol. 2019; 39 (1): p.41-56.doi: 10.1016/j.semnephrol.2018.10.004 . | Open in Read by QxMD
  17. Brown RO, Compher C. A.S.P.E.N. Clinical Guidelines: Nutrition Support in Adult Acute and Chronic Renal Failure. Journal of Parenteral and Enteral Nutrition. 2010; 34 (4): p.366-377.doi: 10.1177/0148607110374577 . | Open in Read by QxMD
  18. Meyer D, Mohan A, Subev E, Sarav M, Sturgill D. Acute Kidney Injury Incidence in Hospitalized Patients and Implications for Nutrition Support. Nutrition in Clinical Practice. 2020; 35 (6): p.987-1000.doi: 10.1002/ncp.10595 . | Open in Read by QxMD
  19. Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020: p.l6722.doi: 10.1136/bmj.l6722 . | Open in Read by QxMD
  20. Vanmassenhove J, Vanholder R, Lameire N. Points of Concern in Post Acute Kidney Injury Management. Nephron. 2017; 138 (2): p.92-103.doi: 10.1159/000484146 . | Open in Read by QxMD
  21. Clinical Practice Guideline Acute Kidney Injury (AKI). Updated: August 1, 2019. Accessed: September 30, 2020.
  22. Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020; 98 (2): p.294-309.doi: 10.1016/j.kint.2020.04.020 . | Open in Read by QxMD
  23. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. Elsevier Saunders ; 2015
  24. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  25. Rahman M, Shad F, Smith MC. Acute kidney injury: a guide to diagnosis and management.. Am Fam Physician. 2012; 86 (7): p.631-9.
  26. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol. 2012; 2 (2): p.1303-53.doi: 10.1002/cphy.c110041 . | Open in Read by QxMD
  27. Prakash J, Singh VP. Changing picture of renal cortical necrosis in acute kidney injury in developing country.. World journal of nephrology. 2015; 4 (5): p.480-6.doi: 10.5527/wjn.v4.i5.480 . | Open in Read by QxMD
  28. Goldman L, Schafer AI. Goldman-Cecil Medicine, 25th Edition. Elsevier ; 2016
  29. Pahwa AK, Sperati CJ. Urinary fractional excretion indices in the evaluation of acute kidney injury. Journal of Hospital Medicine. 2015; 11 (1): p.77-80.doi: 10.1002/jhm.2501 . | Open in Read by QxMD
  30. Manoeuvrier G, Bach-Ngohou K, Batard E, Masson D, Trewick D. Diagnostic performance of serum blood urea nitrogen to creatinine ratio for distinguishing prerenal from intrinsic acute kidney injury in the emergency department. BMC Nephrol. 2017; 18 (1).doi: 10.1186/s12882-017-0591-9 . | Open in Read by QxMD
  31. Schrier RW. Blood Urea Nitrogen and Serum Creatinine. Circulation: Heart Failure. 2008; 1 (1): p.2-5.doi: 10.1161/circheartfailure.108.770834 . | Open in Read by QxMD
  32. MILLER TR. Urinary Diagnostic Indices in Acute Renal Failure. Ann Intern Med. 1978; 89 (1): p.47.doi: 10.7326/0003-4819-89-1-47 . | Open in Read by QxMD
  33. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician. 2005; 71 (6): p.1153-62.
  34. Gotfried J, Wiesen J, Raina R, Nally JV. Finding the cause of acute kidney injury: Which index of fractional excretion is better?. Cleve Clin J Med. 2012; 79 (2): p.121-126.doi: 10.3949/ccjm.79a.11030 . | Open in Read by QxMD
  35. Wilson DR, Wilson DDR. Pathophysiology of obstructive nephropathy. Kidney Int. 1980; 18 (3): p.281-292.doi: 10.1038/ki.1980.138 . | Open in Read by QxMD
  36. Remer EM, Papanicolaou N, Casalino DD, et al. ACR Appropriateness Criteria® on Renal Failure. Am J Med. 2014; 127 (11): p.1041-1048.e1.doi: 10.1016/j.amjmed.2014.05.014 . | Open in Read by QxMD
  37. Podoll A, Walther C, Finkel K. Clinical utility of gray scale renal ultrasound in acute kidney injury. BMC Nephrol. 2013; 14 (1).doi: 10.1186/1471-2369-14-188 . | Open in Read by QxMD
  38. Ather MH, Jafri AH, Sulaiman MN. Diagnostic accuracy of ultrasonography compared to unenhanced CT for stone and obstruction in patients with renal failure. BMC Med Imaging. 2004; 4 (1).doi: 10.1186/1471-2342-4-2 . | Open in Read by QxMD
  39. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2). McGraw-Hill Education / Medical ; 2018
  40. Raina R, Krishnappa V, Blaha T, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis. 2018; 23 (1): p.4-21.doi: 10.1111/1744-9987.12763 . | Open in Read by QxMD
  41. Howard SC, Jones DP, Pui C-H. The Tumor Lysis Syndrome. N Engl J Med. 2011; 364 (19): p.1844-1854.doi: 10.1056/nejmra0904569 . | Open in Read by QxMD
  42. Starr MC, Menon S. Neonatal acute kidney injury: a case-based approach. Pediatr Nephrol. 2021; 36 (11): p.3607-3619.doi: 10.1007/s00467-021-04977-1 . | Open in Read by QxMD
  43. Coleman C, Tambay Perez A, Selewski DT, Steflik HJ. Neonatal Acute Kidney Injury. Front Pediatr. 2022; 10.doi: 10.3389/fped.2022.842544 . | Open in Read by QxMD
  44. Jetton JG, Boohaker LJ, Sethi SK, et al. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. The Lancet Child Adolesc Health. 2017; 1 (3): p.184-194.doi: 10.1016/s2352-4642(17)30069-x . | Open in Read by QxMD
  45. Nada A, Bonachea EM, Askenazi DJ. Acute kidney injury in the fetus and neonate. Semin Fetal Neonatal Med. 2017; 22 (2): p.90-97.doi: 10.1016/j.siny.2016.12.001 . | Open in Read by QxMD

Icon of a lockAccess full content

Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer